StreetAlpha.app
Home › Stocks › ACAD

Acadia Pharmaceuticals Inc (ACAD)

Healthcare
$17.11
▼ −2.73%
LAST CLOSE · NOV 20

Acadia Pharmaceuticals develops and sells medicines for neurological and rare diseases, including NUPLAZID and DAYBUE. It last closed at $17.11 on Nov 20, down 2.73% on the day. The next earnings report for ACAD is expected around Tue, Jan 12, 2027, after the close. For the quarter ended Sep 2026, ACAD reported EPS of $0.31 on revenue of $342.3M, with revenue up 22.8% from a year ago. Over its last 8 reports the stock moved an average of 4.4% the session after earnings. Over the last 12 months ACAD insiders bought $0 of stock on the open market and sold $2.5M, according to SEC Form 4 filings.

AI Auto Pilots
Is ACAD in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ACAD.

Key Stats

Last 12 months
Results
Revenue
$1.2B
+14.8% vs a year ago
Net income
$362.2M
+38.7% vs a year ago
EPS (diluted)
$2.12
+36.8% vs a year ago
Free cash flow
$82.0M
6.8% margin
Valuation
Market cap
$3.0B
172.8M shares
P/E
8.1
Price over 12 month EPS
Price to sales
2.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$322.4M
At Sep 30
Shareholder equity
$1.4B
Shares outstanding
172.8M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $484.1M$484.1MFY2021FY2022: $517.2M$517.2MFY2022FY2023: $726.4M$726.4MFY2023FY2024: $957.8M$957.8MFY2024FY2025: $1.1B$1.1BFY2025

From ACAD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 12
Estimated date · After the close
Reported EPS
$0.31
Quarter ended Sep 2026
Year ago EPS
$0.42
−26.2% on a GAAP basis
Revenue
$342.3M
+22.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.86Dec '24Mar 2025: $0.11Mar '25Jun 2025: $0.16Jun '25Sep 2025: $0.42Sep '25Dec 2025: $1.61Dec '25Mar 2026: $0.02Mar '26Jun 2026: $0.18Jun '26Sep 2026: $0.31Sep '26Latest $0.31
Revenue by quarter
Dec 2024: $259.6MDec '24Mar 2025: $244.3MMar '25Jun 2025: $264.6MJun '25Sep 2025: $278.6MSep '25Dec 2025: $284.0MDec '25Mar 2026: $268.1MMar '26Jun 2026: $308.0MJun '26Sep 2026: $342.3MSep '26Latest $342.3M
How ACAD moved after its last 8 reports
Average move the session after a report ±4.4%
Nov 4, 2026After the close−1.1%
Aug 4, 2026After the close+6.1%
May 6, 2026After the close+5.0%
Feb 25, 2026After the close−1.3%
Jan 13, 2026After the close+1.5%
Nov 5, 2025After the close−3.0%
Aug 6, 2025After the close+2.5%
May 7, 2025After the close+14.3%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ACADStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ACAD
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ACAD

Technical Analysis

ACAD · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 13% below its 20 day and 22% below its 50 day average. It is 35% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot S1 at $16.84, and the nearest resistance the Pivot at $17.32.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 5.5%/day
Key levels
$30.9652 week high+80.9%
$24.14100 day average+41.1%
$23.16200 day average+35.4%
$20.8050 day average+21.6%
$19.44Swing high (Nov 16)+13.6%
$19.3120 day average+12.9%
$17.58Pivot R1+2.7%
$17.32Pivot+1.2%
$17.11Last close
$16.84Pivot S1−1.6%
$15.8652 week low−7.3%
$15.86Swing low (Nov 9)−7.3%
Indicators
RSI (14)34.22Weak, oversold below 30Neutral
MACD-0.93Below its signal lineBearish
Stochastic24.4Middle of its rangeNeutral
ADX (14)32.3Trending down
Williams %R-81.5Oversold below −80, overbought above −20Oversold
CCI (20)-106.9Oversold below −100, overbought above 100Oversold
Rate of change−19.4%Change over 10 sessionsBearish
ATR (14)$0.95Typical daily range, 5.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ACAD

What happened before

See how ACAD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ACAD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ACAD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ACADHow many large options trades hit ACAD, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ACAD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲201 buying vs 152 selling
  • ▼Held by funds -1.0 pts
  • ●Funds holding -1
  • ▼Superinvestors: 1 added, 4 cut
  • ▲Put/call 2.44 to 0.54
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding351352−0.3%
In funds' top 1045−20.0%
Held by funds96.5%97.6%−1.0 pts
New / increased59 / 14246 / 133+12.3%
Reduced / sold out90 / 62111 / 36+3.4%
Put/call ratio0.542.44−77.9%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACAD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ACAD Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$2.5M15 sales · 5 insiders
36% of the selling was under pre-arranged trading plans.
2026-02 sold $162K2026-03 sold $607K2026-04 sold $83K2026-05 sold $220K2026-06 sold $298K2026-07 sold $433K2026-08 sold $587K2026-10 sold $69KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 30Mark C. SchneyerEvp, CFOSale3,321$20.88$69K
Aug 6Mark C. SchneyerEvp, CFOSale plan20,141$29.16$587K
Jul 30Elizabeth H.Z. ThompsonEVP, Head of Research & DevSale16,558$26.13$433K
Jun 26James KiharaPrincipal Accounting OfficerSale plan11,421$26.08$298K
May 26James KiharaPrincipal Accounting OfficerSale5,401$21.18$114K
May 4James KiharaPrincipal Accounting OfficerSale1,332$21.79$29K
Every insider buy and sale for ACAD over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ACAD insider trades →

From SEC Form 4 filings by ACAD's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACAD is in one of them and how their past ACAD trades turned out.

ACAD in the AI portfolios
Loading…

ACAD News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACAD in an article yet. Here's the latest on the wider market.

ACAD in the news

ACAD Congress Trades

All congress trades →
Trades, 12 months
0
Buys
0
Sells
0
People
0
Last filed Jul 28
Who traded ACAD · since 2019
Latest 3 filings
$1K – $15KTraded Jun 16, 2022Filed Jul 28, 2022
Christopher JacobsSell (partial)
$1K – $15KTraded Sep 8, 2020Filed Nov 6, 2020
$1K – $15KTraded Feb 19, 2019Filed Mar 8, 2019
PersonTypeAmountTradedFiledDelay
Christopher JacobsR · NYSell$1K – $15KJun 16, 2022Jul 28, 202242 d
Christopher JacobsR · NYSell (partial)$1K – $15KSep 8, 2020Nov 6, 202059 d
Gilbert CisnerosD · CASell$1K – $15KFeb 19, 2019Mar 8, 201917 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Acadia Pharmaceuticals

Acadia Pharmaceuticals is a drug company based in San Diego, California, that develops and sells medicines for neurological and rare diseases. Its main commercial products are NUPLAZID, used for hallucinations and delusions linked to Parkinson's disease psychosis, and DAYBUE, used to treat Rett syndrome. The company also develops earlier-stage product candidates, including treatments for Alzheimer's disease psychosis. Its medicines are prescribed to patients, mainly in the United States.

Headquarters
San Diego, CA
Founded
1993